iPSC-Derived Cardiomyocytes

01

Differentiation & Maturation

Wnt-Modulated Cardiac Differentiation & Metabolic Selection

I employ Wnt-modulated cardiac differentiation protocols (GiWi method) to direct iPSCs through mesoderm and into cardiomyogenic lineages with high efficiency. The protocol leverages temporal Wnt activation and inhibition to gate mesodermal specification, achieving homogenous cardiomyocyte populations. Post-differentiation, I apply metabolic selection using lactate-containing media to eliminate residual non-contractile cells and enrich beating cardiomyocytes.

Maturation is accelerated through mechanical stimulation (electrical pacing), substrate stiffness tuning, and prolonged culture (60+ days), yielding adult-like sarcomeric organization, gap junction maturity, and electrophysiological properties. These iPSC-CMs are compatible with 96- and 384-well screening formats for high-throughput drug discovery and toxicity profiling.

>90%

cTnT+ cardiomyocytes

60+ days

maturation period

96/384 compatible

well formats

5+ disease lines

banked for modeling

Characterization & QC

Following differentiation, I characterize cardiomyocyte identity via flow cytometry (cTnT, cTnI, α-actinin, TNNT2), immunofluorescence (sarcomeric proteins, gap junctions), and qPCR (cardiac gene panels). Contractile function is confirmed by impedance-based readouts (xCELLigence) and video-based contractility analysis, capturing beating rate, amplitude, and arrhythmia signatures. Lactate assay and glucose consumption quantify metabolic maturation.

RT-qPCR — Cardiomyocyte Differentiation Markers

RT-qPCR quantification confirms cell-type identity and treatment response at the transcriptional level. Expression is normalized to housekeeping genes (GAPDH, ACTB) and presented as fold change relative to undifferentiated or untreated controls. Error bars represent SEM from n=3 biological replicates.

RT-qPCR: Cardiac Gene Expression Profile

Fold change in cardiac markers at Day 30 vs undifferentiated iPSCs (GAPDH-normalized)

ΔΔCt method. n=3 differentiations. Housekeeping: GAPDH, ACTB. *p<0.05, **p<0.01 vs iPSC.

RT-qPCR Expression Heatmap

Relative gene expression across conditions (log₂ fold change)

Color intensity: red = upregulated, blue = downregulated relative to control. Values are log₂(fold change).

02

Electrophysiology & Function

MEA, Calcium Imaging & Contractility Analysis

I assess cardiomyocyte electrophysiology using microelectrode array (MEA) recordings, measuring beat rate, action potential duration, field potential duration (FPD), and arrhythmia liability. Calcium transient imaging (Fluo-4 or GCaMP) reveals spontaneous calcium cycling, kinetics, and drug-induced QT prolongation effects. Video-based contractility analysis (impedance xCELLigence or edge-detection algorithms) quantifies beating frequency, force, and relaxation kinetics across multiwell formats.

Fig. A — MEA: Beat Rate Response to HERG Blockade & Beta Stimulation

Mean beat rate (BPM) in iPSC-CMs exposed to vehicle control, hERG blockers (Dofetilide, E-4031), and sympathomimetic (Isoproterenol)

Axion Maestro MEA. 30-min recording per condition. n=12 wells per drug. Dofetilide and E-4031 induce QT prolongation and negative chronotropic effects; Isoproterenol increases beat rate via β1-adrenergic stimulation.

Fig. B — Calcium Transient Imaging: ΔF/F₀ Traces Under Drug Exposure

Real-time calcium dynamics (ΔF/F₀) in iPSC-CMs: vehicle (normal ~1 Hz pacing), hERG blocker (prolonged transients, reduced frequency), and β-agonist (faster, higher-amplitude beats)

Fluo-4 AM, high-speed confocal imaging. Field-stimulated cardiomyocytes at 1 Hz. Traces represent 4-second windows. Dofetilide induces early afterdepolarization-like prolongation; Isoproterenol increases transient amplitude and frequency.

Fig. C — Field Potential Duration (FPD): Dose-Dependent QT Prolongation

FPD (ms) in iPSC-CMs treated with increasing concentrations of a hERG blocker (E-4031)

MEA-based FPD measurement. Vehicle baseline ~320 ms; dose-dependent prolongation to >450 ms at 100 nM. Linear dose-response indicating hERG IC₅₀ ~30 nM. Arrhythmia onset observed >400 ms FPD.

03

Cardiotoxicity Screening

High-Content Screening & Viability Assays

I perform high-content screening for structural and functional cardiotoxicity, quantifying sarcomeric disarray, mitochondrial dysfunction, and cell viability. CellTiter-Glo luminescence viability assays measure ATP-dependent metabolic activity across dose ranges. Impedance-based monitoring (xCELLigence Real-Time Cell Analyzer) tracks cell index changes reflecting contractile dysfunction and cardiomyocyte death. These readouts enable IC₅₀ determination, safety margin assessment, and compound rank-ordering for cardiotoxicity liability.

Fig. D — Dose-Response Viability: CellTiter-Glo Cardiotoxicity Profiling

% viability (ATP levels normalized to vehicle) in iPSC-CMs exposed to chemotherapy (Doxorubicin), targeted kinase inhibitor (Sunitinib), vehicle, and positive control across log-scaled concentrations

CellTiter-Glo assay at 72 h. Doxorubicin: IC₅₀ ~0.5 μM (high cardiotoxicity); Sunitinib: IC₅₀ ~8 μM (moderate toxicity); Vehicle/Ctrl: no toxicity. n=6 replicates per dose.

Fig. E — Impedance Monitoring: Real-Time Contractile Dysfunction

Cell Index over 72 hours in iPSC-CMs treated with vehicle, low-dose, and high-dose cardiotoxicant

xCELLigence RTCA. Vehicle stable (CI ~1.0); low dose shows modest decline (~0.8); high dose shows progressive loss of contractile function (CI drops to ~0.4 by 72 h). Data reflects loss of impedance from cardiomyocyte contraction and viability.

04

Disease Modeling

HCM, DCM & Arrhythmia Models

I generate patient-derived iPSC-cardiomyocytes from individuals with hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and long-QT syndrome (LQTS). Using CRISPR-Cas9 gene editing, I create isogenic lines carrying disease mutations (MYH7, TTN, LMNA, KCNH2) to isolate genetic effects. These models recapitulate disease phenotypes including abnormal sarcomere organization, impaired calcium handling, action potential prolongation, and spontaneous arrhythmia signatures. Rescue experiments and small-molecule screening identify therapeutic candidates.

Fig. F — Sarcomere Organization: Disease-Associated Disarray

Quantified sarcomere organization score (0–100 scale; higher = more organized) in isogenic iPSC-CMs: wild-type control, HCM-MYH7 mutation, DCM-TTN truncation, and LMNA-p.R349W

α-actinin immunofluorescence with automated image analysis (ImageJ, Orca). WT: 82±5 (organized Z-disc spacing, sarcomere length 1.9–2.1 μm); HCM-MYH7: 48±8 (disarray, hypertrophy); DCM-TTN: 35±7 (severe disarray, Z-disc fragmentation); LMNA: 42±6 (nuclear abnormality, secondary sarcomeric disarray). n=100 cells per line.

+

Methods

Detailed Methodology & Techniques

Comprehensive descriptions of key experimental techniques, assay platforms, and analytical methods referenced throughout this page.

Contractility Analysis

I measure iPSC-CM contractility using high-speed video microscopy and automated contraction analysis (MUSCLEMOTION, CyteSeer). Parameters include contraction amplitude, velocity, relaxation time, and beat-to-beat variability. Impedance-based contractility (xCELLigence CardioECR) provides continuous, label-free monitoring of beating kinetics over days to weeks, enabling longitudinal drug response studies.

Fig. — Contractility Parameters

Contraction amplitude and velocity across iPSC-CM maturation timepoints

Video microscopy + MUSCLEMOTION analysis. n=8 wells per timepoint.

Action Potential Recording

I characterize iPSC-CM action potentials using voltage-sensitive dyes (FluoVolt, di-8-ANEPPS) and optical mapping. Key parameters include APD30, APD50, APD90 (action potential duration at 30/50/90% repolarization), upstroke velocity, and resting membrane potential. These optical AP recordings are validated against patch-clamp electrophysiology and are used to classify iPSC-CMs as ventricular, atrial, or nodal-like phenotypes.

Fig. — Action Potential Duration (APD)

APD30, APD50, and APD90 across ventricular, atrial, and nodal-like iPSC-CMs

FluoVolt optical mapping. n=12 cells per subtype. Mean ± SEM.

High-Content Screening

I operate the Opera Phenix and ArrayScan high-content imaging platforms for automated multi-parametric analysis of iPSC-CMs. Endpoints include sarcomere organization (α-actinin pattern analysis), mitochondrial morphology (TMRM/MitoTracker), nuclear morphology, and calcium handling (Fluo-4 kinetics). These assays support compound screening campaigns at 96- and 384-well scale with automated image analysis pipelines.

iPSC-CM Differentiation & Functional Assessment Platform

Wnt-modulated cardiac differentiation through metabolic selection, electrophysiological characterization, and multi-parameter safety pharmacology endpoints for drug discovery and cardiotoxicity profiling.

Day 0–1

Wnt Activation

CHIR99021 GSK3β inhibition. Mesoderm specification.

GiWi PROTOCOL

Day 3–5

Wnt Inhibition

IWP2/IWP4 Wnt antagonism. Cardiac mesoderm commitment.

SPECIFICATION

Day 7–10

Spontaneous Beating

First contractile activity. Visual QC of beating monolayers.

CONTRACTION

Day 10–15

Metabolic Selection

Lactate media purification. Eliminate non-CM cells. >90% cTnT⁺.

PURIFICATION

Day 30–60+

Maturation

Electrical pacing, substrate stiffness. Adult-like sarcomeric organization.

MATURATION

Day 60+

Assay-Ready

96/384-well formats. HCS, MEA, calcium, impedance compatible.

SCREENING

MEA

Electrophysiology (MEA)

Axion Maestro multiwell array

Beat Rate

Spontaneous & paced. BPM across conditions.

FPDc

Corrected field potential duration — QT prolongation surrogate.

Conduction

Conduction velocity mapping. Arrhythmia detection.

Drug Response

hERG blockers (Dofetilide, E-4031), isoproterenol, nifedipine.

Ca²⁺

Calcium Transient Imaging

Fluo-4 / GCaMP reporters

Amplitude

ΔF/F₀ peak calcium transient magnitude.

CTD50/90

Calcium transient duration at 50% and 90% decay.

Rise Time

Time to peak calcium — SR release kinetics.

Irregularity

Beat-to-beat variability & arrhythmia scoring.

Tox

Cardiotoxicity & Safety

Multi-parameter injury endpoints

cTnI / LDH

Cardiac troponin I and lactate dehydrogenase release — injury markers.

hERG

Channel pharmacology — IC₅₀ determination for QT liability.

Impedance

xCELLigence real-time monitoring. Continuous viability tracking.

Structural

Sarcomeric disarray ICC. α-actinin, cTnT, connexin-43 integrity.

HCS

High-Content Screening

96/384-well automated imaging

Viability

CellTiter-Glo, Live/Dead, Calcein/EthD-1 multiplexing.

Morphology

Cell area, circularity, sarcomeric alignment quantification.

Contractility

Video-based edge detection. Beat amplitude, frequency, relaxation.

Dose-Response

8-point curves, IC₅₀/EC₅₀ fitting. Z-factor quality metrics.

Disease Models Banked

Hypertrophic CM (HCM)

MYH7 / MYBPC3 mutations. Sarcomeric hypertrophy, diastolic dysfunction.

Dilated CM (DCM)

TTN / LMNA variants. Contractile impairment, reduced force generation.

Long QT Syndrome

KCNQ1 / hERG mutations. Prolonged APD, arrhythmia liability.

Brugada Syndrome

SCN5A variants. Conduction abnormalities, VF risk assessment.

Drug Cardiotoxicity

Doxorubicin, tyrosine kinase inhibitors. Structural & functional injury profiling.

Fig. — HCS Multi-Parametric Cardiac Panel

Z-scores for sarcomere, mitochondrial, nuclear, and calcium endpoints across compound library

Opera Phenix HCS. 384-well. 10 fields/well. Columbus analysis.

Wnt-Modulated Cardiac Differentiation & Metabolic Selection

MEA, Calcium Imaging & Contractility Analysis

High-Content Screening & Viability Assays

HCM, DCM & Arrhythmia Models

Detailed Methodology & Techniques

iPSC-Cardiomyocyte Pipeline